95 related articles for article (PubMed ID: 27530731)
1. Plumbagin Enhances Tamoxifen Sensitivity and Inhibits Tumor Invasion in Endocrine Resistant Breast Cancer through EMT Regulation.
Sakunrangsit N; Kalpongnukul N; Pisitkun T; Ketchart W
Phytother Res; 2016 Dec; 30(12):1968-1977. PubMed ID: 27530731
[TBL] [Abstract][Full Text] [Related]
2. NADPH: Quinone oxidoreductase 1 (NQO1) mediated anti-cancer effects of plumbagin in endocrine resistant MCF7 breast cancer cells.
Pradubyat N; Sakunrangsit N; Mutirangura A; Ketchart W
Phytomedicine; 2020 Jan; 66():153133. PubMed ID: 31790893
[TBL] [Abstract][Full Text] [Related]
3. Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer.
Sakunrangsit N; Ketchart W
Pharmacol Res; 2019 Dec; 150():104517. PubMed ID: 31693936
[TBL] [Abstract][Full Text] [Related]
4. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.
Qiu JX; Zhou ZW; He ZX; Zhao RJ; Zhang X; Yang L; Zhou SF; Mao ZF
Drug Des Devel Ther; 2015; 9():349-417. PubMed ID: 25609920
[TBL] [Abstract][Full Text] [Related]
5. Plumbagin inhibited AKT signaling pathway in HER-2 overexpressed-endocrine resistant breast cancer cells.
Sakunrangsit N; Ketchart W
Eur J Pharmacol; 2020 Feb; 868():172878. PubMed ID: 31863768
[TBL] [Abstract][Full Text] [Related]
6. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells.
Wang F; Wang Q; Zhou ZW; Yu SN; Pan ST; He ZX; Zhang X; Wang D; Yang YX; Yang T; Sun T; Li M; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():537-60. PubMed ID: 25632222
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
8. Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
Bui QT; Im JH; Jeong SB; Kim YM; Lim SC; Kim B; Kang KW
Cancer Lett; 2017 Apr; 390():115-125. PubMed ID: 28108315
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features.
Shi XP; Miao S; Wu Y; Zhang W; Zhang XF; Ma HZ; Xin HL; Feng J; Wen AD; Li Y
Int J Mol Sci; 2013 Jul; 14(8):15655-68. PubMed ID: 23896596
[TBL] [Abstract][Full Text] [Related]
11. MHP-1 inhibits cancer metastasis and restores topotecan sensitivity via regulating epithelial-mesenchymal transition and TGF-β signaling in human breast cancer cells.
Lin S; Lyu X; Yu J; Sun L; Du D; Lai Y; Li H; Wang Y; Zhang L; Yin H; Yuan S
Phytomedicine; 2016 Sep; 23(10):1053-63. PubMed ID: 27444351
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
13. Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.
Carriere PP; Llopis SD; Naiki AC; Nguyen G; Phan T; Nguyen MM; Preyan LC; Yearby L; Pratt J; Burks H; Davenport IR; Nguyen TA; Parker-Lemieux K; Payton-Stewart F; Williams CC; Boué SM; Burow ME; Collins-Burow B; Hilliard A; Davidson AM; Tilghman SL
Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010010. PubMed ID: 26703648
[TBL] [Abstract][Full Text] [Related]
14. miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.
Fu H; Fu L; Xie C; Zuo WS; Liu YS; Zheng MZ; Yu JM
Oncol Rep; 2017 Feb; 37(2):1093-1099. PubMed ID: 28075453
[TBL] [Abstract][Full Text] [Related]
15. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
16. EGFR inhibition reverses epithelial‑mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells.
Takeda T; Tsubaki M; Matsuda T; Kimura A; Jinushi M; Obana T; Takegami M; Nishida S
Oncol Rep; 2022 Jun; 47(6):. PubMed ID: 35445730
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory Effects of Plumbagin on Retinal Pigment Epithelial Cell Epithelial-Mesenchymal Transition In Vitro and In Vivo.
Chen H; Wang H; An J; Shang Q; Ma J
Med Sci Monit; 2018 Mar; 24():1502-1510. PubMed ID: 29532788
[TBL] [Abstract][Full Text] [Related]
19. Salinomycin overcomes acquired tamoxifen resistance through AIB1 and inhibits cancer cell invasion in endocrine resistant breast cancer.
Manmuan S; Sakunrangsit N; Ketchart W
Clin Exp Pharmacol Physiol; 2017 Oct; 44(10):1042-1052. PubMed ID: 28656701
[TBL] [Abstract][Full Text] [Related]
20. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
